RxDoctor Payments Data

Jose Llamas, MD

General Practice · Leesburg, FLNPI 1366996738

Payments from drug & device makers

$1,324in general payments, 2019–2025

Across 37 payments — averaging $35.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$209
  • KARL Storz Endoscopy-america$178
  • Exact Sciences$156
  • GSK$113
  • Johnson & Johnson$103
  • Conmed Corporation$100
  • plus $466 from 10 others

What the payments were for

  • Food & beverage$1,324100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,324 in reported general payments places this provider in the 80th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$8,624
Medicare patients
49
Services billed
93

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban49$55,572
FarxigaDapagliflozin Propanediol31$33,915
OzempicSemaglutide19$33,235
JardianceEmpagliflozin27$31,232
TrulicityDulaglutide25$28,390
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$3,542
Gabapentin91$2,816
Rosuvastatin Calcium291$2,399
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$2,065
LantusInsulin Glargine,hum.Rec.Anlog18$1,985
Memantine Hcl38$1,794
Levothyroxine Sodium146$1,584
Atorvastatin Calcium184$1,281
Albuterol Sulfate HfaAlbuterol Sulfate62$1,198
Omeprazole119$1,110

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$20$55,57249 claims
AstraZenecaFarxiga$209$33,91531 claims
Novo NordiskOzempic$53$33,23519 claims
Boehringer IngelheimJardiance$82$31,23227 claims
Lilly USA, LLCTrulicity$39$28,39025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,901 general practice providers in Florida.

Other general practice in Leesburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →